Mymetics Corp (MYMX)

[FALCON1]

Is it possible that the comparator vaccine under SEC "confidential treatment order" mentioned in the agreement between Mymetics and Sanofi Pasteur is FLUZONE? Is it possible Sanofi is planning to make an intra-nasal delivery version of FLUZONE to compete with Aztra Zeneca's FLUMIST? Bottom line these are good possibilities in addition to Sanofi's possible intent to improve effectiveness and cost competitiveness of their flu vaccine as well as other current/future virus-based vaccines.


"There's also the prevailing myth that getting a flu shot will give you the flu, which isn't true. With the exception of AstraZeneca's (NYSE:AZN) live attenuated vaccine known as FluMist, the other vaccines are comprised of inactive flu strains. Think of them as a teaching tool for your immune system so it understands how to fight the flu should you be infected. Even if you take AstraZeneca's FluMist, the dosage is low enough to not cause someone to develop the flu. At worst, the patient will come down with minor cold symptoms.

Presumably, if more people got a flu shot, there could be fewer flu-related deaths each year.

The proliferation of new vaccines offers promise
The researchers that develop seasonal flu vaccines have been focusing on a new type of flu vaccine in recent years known as a quadrivalent. Previous vaccines before the quadrivalent focused on three strains each year: two influenza type A strains and a single type B strain (and were thus known as trivalent vaccines). The new quadrivalent vaccines, which have been on the market for a few years and are beginning to grow in use, combine two type A and two type B strains. The hope is that these new vaccines will provide better vaccine effectiveness in the later half of flu season when type B strains are more prevalent.

There are a number of quadrivalent options for consumers to choose from this season. One option that is available -- but which the CDC suggests you steer clear -- is AstraZeneca's nasal spray FluMist. Despite being a handy alternative to getting a shot, studies have suggested that FluMist simply isn't effective compared to the other flu vaccines being offered.

Doctor administering a flu vaccine to an elderly patient
IMAGE SOURCE: GETTY IMAGES.

The most popular flu vaccine year in and year out continues to be Sanofi's (NYSE:SNY) FluZone, which has topped the $1 billion sales mark in previous years depending on the severity and public worry surrounding the flu.

There are three aspects of FluZone that allow it to stand out head and shoulders above its peers. First, FluZone is approved to treat infants as young as six months old. Many of Sanofi's peers have considerably higher lowest-age treatment recommendations. Second, FluZone has a dosing option that features a needle that's 90% shorter than a traditional needle, which a nice option for those who are needle-phobic, and for children. Lastly, FluZone isn't a one-size-fits-all vaccine. There are around a half-dozen different dosing options, which makes it a preferred choice of physicians.

The flu vaccine is never going to be perfect, nor is it ever going to be able to prevent people from getting the flu. However, the data would suggest it does a good job more often than not of reducing the severity of the disease in people should they come down with the flu".


https://www.fool.com/investing/2017/02/11/flu-death-rates-just-hit-the-epidemic-threshold-bu.aspx



Mymetics and Sanofi Pasteur Research Agreement

https://www.sec.gov/Archives/edgar/data/927761/000165495416004430/mymx_ex101.htm





regards